Trastuzumab beyond progression in HER2-positive metastatic breast cancer

被引：1
|
作者：
Al-Naqqash, Manwar [1 ,2 ]
Jasim Al-Serarati, Waleed [3 ]
Farooq Kareem, Tara [4 ]
机构：
[1] Univ Baghdad, Dept Surg, Coll Med, Baghdad 10001, Iraq
[2] Minist Hlth Environm, Dept Radiat Oncol, Oncol Teaching Hosp, Baghdad Med City Complex, Baghdad, Iraq
[3] Minist Hlth & Environm, Dept Oncol, Baghdad Med City Complex, Baghdad, Iraq
[4] Minist Hlth & Environm, Oncol Teaching Hosp, Dept Diagnost Radiol, Baghdad Med City Complex, Baghdad, Iraq
来源：
BREAST JOURNAL | 2021年 / 27卷 / 03期
关键词：
breast cancer; HER2; neu; time to progression; trastuzumab;
D O I：
10.1111/tbj.14157
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：297 / 299
页数：3
相关论文
共 50 条
  • [11] Trastuzumab therapy in HER2-positive, metastatic breast cancer
    Smith, A. D.
    Guilbert, K.
    Lister, D.
    Streilein, S.
    Bourrier, V. C.
    Lozar, B.
    Navaratnam, S.
    Harding, G. A.
    Pitz, M. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [12] Trastuzumab Deruxtecan in HER2-positive metastatic Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2024, 84 (08) : 670 - 670
  • [13] Use of trastuzumab in HER2-positive metastatic breast cancer beyond disease progression: a systematic review of published studies
    Mannocci, Alice
    De Feo, Emma
    de Waurel, Chiara
    Specchia, Maria Lucia
    Gualano, Maria Rosaria
    Barone, Carlo
    Ricciardi, Walter
    La Torre, Giuseppe
    TUMORI JOURNAL, 2010, 96 (03): : 385 - 391
  • [14] HER2-positive breast cancer cells percentage and progression to trastuzumab treatment in metastatic patients
    Garcia-Garcia, Y.
    Martinez-Fernandez, A.
    Munoz Mateu, M.
    Fernandez-Ruiz, P.
    Garcia-Albeniz, X.
    Marmol-Casas, M.
    Domingo-Domenech, J.
    Pineda-Losada, E.
    Visa-Turmo, L.
    Gascon Vilaplana, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [15] Trastuzumab beyond progression in HER2-positive advanced breast cancer: The Royal Marsden experience
    T Waddell
    A Kotsori
    A Constantinidou
    N Yousaf
    S Ashley
    M Parton
    M Allen
    N Starling
    P Papadopoulos
    M O'Brien
    I Smith
    S Johnston
    British Journal of Cancer, 2011, 104 : 1675 - 1679
  • [16] Trastuzumab beyond Progression in HER2-Positive Advanced Breast Cancer: The Royal Marsden Experience
    Waddell, T.
    Kotsori, A.
    Constantinidou, A.
    Yousaf, N.
    Ashley, S.
    Parton, M.
    Johnston, S.
    Smith, I.
    CANCER RESEARCH, 2010, 70
  • [17] Trastuzumab beyond progression in HER2-positive advanced breast cancer: The Royal Marsden experience
    Waddell, T.
    Kotsori, A.
    Constantinidou, A.
    Yousaf, N.
    Ashley, S.
    Parton, M.
    Allen, M.
    Starling, N.
    Papadopoulos, P.
    O'Brien, M.
    Smith, I.
    Johnston, S.
    BRITISH JOURNAL OF CANCER, 2011, 104 (11) : 1675 - 1679
  • [18] Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
    Swain, Sandra M.
    Baselga, Jose
    Kim, Sung-Bae
    Ro, Jungsil
    Semiglazov, Vladimir
    Campone, Mario
    Ciruelos, Eva
    Ferrero, Jean-Marc
    Schneeweiss, Andreas
    Heeson, Sarah
    Clark, Emma
    Ross, Graham
    Benyunes, Mark C.
    Cortes, Javier
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (08): : 724 - 734
  • [19] Paclitaxel, carboplatin, and trastuzumab in HER2-positive metastatic breast cancer
    Andrew D. Seidman
    Larry Norton
    Current Oncology Reports, 2005, 7 (1) : 9 - 11
  • [20] Role of trastuzumab in the management of HER2-positive metastatic breast cancer
    Milani, Andrea
    Montemurro, Filippo
    Gioeni, Luisa
    Aglietta, Massimo
    Valabrega, Giorgio
    BREAST CANCER-TARGETS AND THERAPY, 2010, 2 : 93 - 109
12345